| 000 | 01222 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517213022.0 | ||
| 264 | 0 | _c20191108 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1526-4610 | ||
| 024 | 7 |
_a10.1111/head.13305 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEdvinsson, Lars | |
| 245 | 0 | 0 |
_aThe CGRP Pathway in Migraine as a Viable Target for Therapies. _h[electronic resource] |
| 260 |
_bHeadache _c05 2018 |
||
| 300 |
_a33-47 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aCalcitonin Gene-Related Peptide _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCalcitonin Gene-Related Peptide Receptor Antagonists _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMigraine Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Calcitonin Gene-Related Peptide _xmetabolism |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTryptamines _xadministration & dosage |
| 773 | 0 |
_tHeadache _gvol. 58 Suppl 1 _gp. 33-47 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/head.13305 _zAvailable from publisher's website |
| 999 |
_c28328382 _d28328382 |
||